Barinthus Biotherapeutics plc American Depositary Shares (BRNS) is a publicly traded Healthcare sector company. As of May 21, 2026, BRNS trades at $0.69 with a market cap of $26.08M and a P/E ratio of -0.42. BRNS moved +2.41% today. Year to date, BRNS is -5.52%; over the trailing twelve months it is -22.81%. Its 52-week range spans $0.51 to $2.92. Analyst consensus is buy with an average price target of $7.00. Rallies surfaces BRNS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BRNS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BRNS recently traded at $0.69. Market cap is $26.08M. P/E ratio is -0.42. Revenue is $506.00K.
| Metric | Value |
|---|---|
| Price | $0.69 |
| Market Cap | $26.08M |
| P/E Ratio | -0.42 |
| EPS | $-1.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.92 |
| 52-Week Low | $0.51 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $506.00K |
| Net Income | $-66.46M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $506.00K | $-66.46M | $-1.64 |
| 2024 | $14.97M | $-61.18M | $-1.55 |
| 2023 | $802.00K | $-73.45M | $-1.91 |
1 analysts cover BRNS: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.00.